Bard PowerPort Catheter Failure Lawsuits 2026: Fractures, Infections & Your Legal Rights
Bard PowerPort Catheter Failure Lawsuits
When a medical device is surgically implanted in your body to deliver chemotherapy, antibiotics, or long-term medication, you place absolute trust in it. You trust that it was designed safely. That it was tested thoroughly. That the company who made it told your doctor everything they needed to know. For thousands of patients implanted with the Bard PowerPort — a subcutaneous venous access device manufactured by C.R. Bard, now owned by Becton, Dickinson and Company (BD) — that trust was broken in one of the most frightening ways imaginable: a fracture inside their body, with pieces of catheter migrating toward their heart.
By 2026, Bard PowerPort lawsuits have grown into one of the most significant active medical device litigations in the United States, consolidated in MDL 3081 in the District of Arizona. Thousands of patients are seeking answers — and compensation — for catheter fractures, migrations, life-threatening infections, and cardiac events that they allege were caused by a defective device and a manufacturer that failed to warn them of the risks.
This guide explains the full picture: what went wrong, what the FDA records show, where the litigation stands, who qualifies to file, and what compensation looks like in both the USA and UK in 2026.
What Is the Bard PowerPort?
An implantable port (also known as a port-a-cath or totally implantable venous access device) is a small medical device surgically placed under the skin — typically in the upper chest — to provide reliable, repeated, long-term access to the central venous system. The device consists of two parts: a port (a small reservoir with a self-sealing silicone septum) and a catheter (flexible tubing) that extends from the port through a vein to the superior vena cava — the large vein that feeds directly into the heart.
Once implanted, the port allows healthcare providers to administer medications, draw blood, or infuse contrast dye simply by inserting a needle through the skin into the port reservoir — without finding a new vein each time. For patients undergoing months of chemotherapy, this convenience is clinically significant: it protects peripheral veins from the damaging effects of repeated venipuncture and powerful drugs.
What Makes the Bard PowerPort Different
The Bard PowerPort was specifically engineered as a power-injectable port — designed to withstand the high-pressure injections required for CT contrast studies (typically 300–600 psi injection pressure). A standard venous access port cannot tolerate these pressures. The PowerPort's power-injectable designation made it particularly popular in oncology and interventional radiology settings, where imaging is frequent and patients need both chemotherapy access and CT-compatible venous access in one device.
C.R. Bard marketed the PowerPort across multiple generations and configurations. The catheter material in various Bard port products has included polyurethane formulations — a material choice that plaintiffs allege contributed to the fracture failures at the centre of the litigation.
With millions of Bard port devices implanted over its product lifetime across the United States, the potential scale of harm — and litigation — is substantial.
The Failure Pattern: What Has Gone Wrong
Adverse event reports submitted to the FDA's MAUDE (Manufacturer and User Facility Device Experience) database, combined with plaintiffs' accounts and medical literature, describe a consistent and disturbing pattern of Bard PowerPort failures.
Catheter Fracture and Embolism
The most serious and most commonly litigated failure is catheter fracture — the breaking of the catheter component, with fragments entering the bloodstream.
Fractures most frequently occur:
- At the catheter-port junction: Where the catheter connects to the port reservoir body, creating a stress concentration point under repeated movement and high-pressure injection cycles
- Along the catheter body: Particularly at points where the catheter passes over or near the clavicle (collarbone), where repetitive movement during normal arm and shoulder activity creates cyclic stress
- At the catheter tip: Less commonly, the distal tip may separate
When a fracture occurs, the detached fragment enters the venous bloodstream and follows the path of blood flow — toward the heart and lungs. Catheter embolism can cause:
- Cardiac arrhythmia: Fragment lodging in cardiac chambers or against valve leaflets
- Pulmonary embolism: Fragment migrating into pulmonary arteries, blocking blood flow
- Vessel perforation: Fragment puncturing vessel walls
- Cardiac tamponade: Fragment perforating the heart wall, causing blood accumulation in the pericardial sac — a potentially fatal emergency
Fragment retrieval typically requires interventional radiology procedures (snare retrieval through catheter techniques) costing $15,000–$40,000, or in severe cases, open cardiac surgery costing $50,000–$150,000+. Even successful retrieval involves hospitalisation, risk of procedural complications, and significant physical and psychological trauma.
Catheter Migration Without Fracture
Intact catheters have also been reported to migrate — shifting from their intended position in the superior vena cava to other locations including the right atrium, right ventricle, or other vessels. Migration can cause arrhythmia, thrombosis, or vessel damage, and typically requires repositioning or replacement.
Port Thrombosis and Occlusion
Device-associated blood clots are a known complication of any implanted venous device. Extensive clotting can cause deep vein thrombosis (DVT), superior vena cava (SVC) syndrome — a serious condition involving venous obstruction in the upper body — or pulmonary embolism. Plaintiffs allege that design features of Bard ports contributed to elevated thrombotic risk.
Infections and Sepsis
Port-site infections are a recognised complication of implanted devices, but plaintiffs in this litigation allege that material or design features of Bard PowerPort devices were associated with elevated infection rates. In cancer patients — who are often immunocompromised from chemotherapy — a port infection can rapidly escalate to septicemia (blood poisoning), with a mortality rate of 20–30% in the most vulnerable patients.
Device Malfunction Under Power Injection
Some patients report that their Bard PowerPort failed during high-pressure CT contrast injection — either leaking at the port-catheter junction or occluding — causing contrast extravasation (leakage into surrounding tissue), injection failure, or device damage.
What Plaintiffs Allege About Bard/Becton Dickinson
The legal claims in the Bard PowerPort MDL are not simply that patients were harmed — they are that Becton Dickinson knew about these risks and failed to act responsibly. Plaintiffs allege through MDL discovery:
Design deficiency: The catheter's polyurethane composition, wall thickness, and structural design at stress points — particularly the port-catheter junction and the collarbone crossover point — were insufficient to withstand the foreseeable mechanical stresses of long-term implantation combined with power injection cycles.
Failure to warn: Healthcare providers were not given adequate information about the catheter fracture and embolism risk, preventing them from having meaningful informed consent discussions with patients or from implementing enhanced monitoring protocols.
Inadequate post-market surveillance: Adverse event reports to the FDA's MAUDE database — including reports of catheter fractures and embolisms — were received over an extended period without triggering adequate product redesign, enhanced warnings, or voluntary recall.
Negligent testing: Pre-market testing of the PowerPort catheter did not adequately simulate the real-world conditions of long-term implantation plus repeated high-pressure injection cycles over months and years.
FDA Records and Regulatory Actions
The FDA's MAUDE database contains hundreds of adverse event reports for Bard vascular access products documenting catheter fractures, migrations, embolisms, and infections. Multiple Class II recalls — defined by the FDA as situations where use of the recalled product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote but possible — have been issued for Bard port and catheter products over the years.
A Class II recall does not mean the FDA has determined the device is defective — but it does create a documented regulatory record of known device performance concerns that plaintiffs' attorneys use to establish the manufacturer's awareness of problems.
MDL 3081: The Litigation in 2026
Consolidation
Bard PowerPort lawsuits were consolidated into MDL 3081 — In Re: Bard PowerPort MDL — in the District of Arizona, assigned to Judge David G. Campbell, a jurist with extensive MDL experience, including prior leadership of the Bard IVC Filter MDL. This prior experience with Bard vascular device litigation is considered significant — attorneys and observers expect efficient management of discovery and bellwether proceedings.
As of early 2026, the MDL contains 3,000+ active cases from plaintiffs nationwide. New cases continue to be filed as patients who experienced complications learn of the litigation.
Discovery Progress
MDL discovery is in active progress in 2026. Key discovery includes:
- Bard/BD internal engineering documents and design testing records
- Post-market surveillance data and adverse event report analysis
- Internal communications about catheter performance concerns
- Sales and marketing materials for the PowerPort
- Medical literature known to the company at relevant times
Internal document discovery in device MDLs frequently produces the most compelling evidence for plaintiffs — revealing what the company knew and when.
Bellwether Trial Trajectory
Judge Campbell has extensive experience with bellwether trial processes from the Bard IVC Filter MDL, where early trials produced verdicts ranging from defence wins to a $3.6 million plaintiff verdict. The bellwether trial selection and scheduling process for MDL 3081 is ongoing, and first bellwether trials are anticipated within 12–24 months. These results will drive global settlement negotiations.
USA: Costs, Eligibility & Compensation
Eligibility Checklist
To assess whether you have a viable Bard PowerPort claim, work through this checklist:
✅ You had a Bard PowerPort or Bard-branded implantable port — confirmed via implant card, surgical records, or hospital documentation
✅ You experienced a qualifying complication — catheter fracture, fragment embolism, catheter migration, serious infection (sepsis), device malfunction, or other device-related harm
✅ Additional medical intervention was required — anything beyond routine port removal: interventional radiology, emergency hospitalisation, retrieval surgery, treatment for sepsis, or replacement surgery
✅ Physical harm resulted — injury, pain, medical costs, lost time, or permanent consequences
✅ You are within the statute of limitations — typically 2–3 years from the injury event or date of discovery
Statute of Limitations by Key States
| State | Deadline | Notes |
|---|---|---|
| California | 2 years from discovery | Discovery rule applies |
| New York | 3 years from injury | Strict application |
| Texas | 2 years from injury | Expert report required |
| Florida | 2 years from discovery | Changed from 4 years in 2023 |
| Pennsylvania | 2 years from discovery | |
| Illinois | 2 years from discovery |
Compensation Categories and Values
Economic damages:
| Item | USA Cost Range |
|---|---|
| Interventional radiology retrieval | $15,000–$40,000 |
| Open cardiac or thoracic surgery | $50,000–$150,000+ |
| ICU hospitalisation for sepsis (per day) | $5,000–$20,000 |
| Port replacement surgery | $8,000–$25,000 |
| Lost wages (30-day recovery minimum) | Varies by income |
| Ongoing cardiac monitoring | $1,000–$5,000/year |
Non-economic damages:
- Pain and suffering during the complication, procedures, and recovery
- Emotional distress — particularly significant for cancer patients whose treatment was interrupted
- Fear of recurrence or permanent cardiac consequences
- Loss of enjoyment of life
Realistic Settlement Ranges (USA 2026)
| Injury Severity | Estimated Settlement Range |
|---|---|
| Fracture, successful IR retrieval, full recovery | $75,000–$200,000 |
| Fracture + cardiac/pulmonary embolism, hospitalisation | $150,000–$400,000 |
| Permanent cardiac or pulmonary damage | $300,000–$800,000+ |
| Sepsis requiring prolonged ICU care | $200,000–$600,000 |
| Wrongful death from device failure | $500,000–$2,000,000+ |
Top Law Firms Handling Bard PowerPort Cases
- Levin Papantonio Rafferty (Pensacola, FL) — among the most prominent pharmaceutical and device litigation firms nationally
- Motley Rice LLC (Mount Pleasant, SC) — major medical device MDL firm
- Seeger Weiss LLP (New York, NY) — significant MDL leadership experience
- Keller Postman LLC (Chicago, IL) — active mass tort and device practice
- Aylstock, Witkin, Kreis & Overholtz (Pensacola, FL) — specialist medical device litigation firm
All work on contingency — $0 upfront. Legal fees (33–40%) deducted from recovery only if successful.
UK: Implantable Device Claims
The Bard PowerPort and other Bard/BD vascular access devices have been used in UK hospitals, both NHS and private, through procurement agreements with BD. UK patients who experienced device-related complications may have legal options.
Legal Framework
Product Liability (Consumer Protection Act 1987): Manufacturers of medical devices are liable for defective products that cause personal injury, without the need to prove negligence. A catheter that fractures during normal implantation and use — causing embolism or other injury — may constitute a product defect under this framework.
Clinical Negligence: If a UK healthcare provider (NHS or private) failed to adequately investigate reported symptoms, failed to act on imaging showing catheter migration, or failed to remove a device showing signs of failure in a timely manner, a clinical negligence claim against the provider may also be available in addition to the product liability claim.
MHRA Reporting: Any device failure involving a Bard PowerPort in the UK should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card system. This creates an official adverse event record and contributes to regulatory oversight.
UK Costs and Funding
| Item | UK Cost |
|---|---|
| Interventional retrieval procedure (private) | £12,000–£30,000 |
| Open cardiac surgery (private) | £30,000–£80,000 |
| NHS treatment (if covered) | No patient cost |
| Solicitor fees (No Win No Fee) | 25% of damages if successful |
Time limits: 3 years from date of injury or date of knowledge. No Win No Fee representation from specialist medical device solicitors.
Practical Steps: What to Do Right Now
Step 1: Locate Your Implant Card
Your implant card — provided at the time of surgery — identifies the device manufacturer (Bard/BD), model name (PowerPort), and lot number. If you no longer have it, your surgical centre is required to maintain implant records.
Step 2: Request Complete Medical Records
Obtain all records related to your port placement, any imaging performed during your treatment course (chest X-rays, CT scans — these may show catheter position or fracture), the complication event, and any subsequent procedures.
Step 3: Get a Cardiac/Pulmonary Evaluation if Needed
If you experienced unexplained chest pain, palpitations, or shortness of breath following your catheter complication, ensure you have had appropriate cardiac and pulmonary evaluation. Medical documentation of any cardiac or pulmonary consequences of the device failure is important for your claim.
Step 4: Document Your Experience in Detail
Write a complete timeline: device placement date, any symptoms you noticed, when the complication was discovered, what procedures were performed, your recovery, and how the experience affected your cancer treatment timeline, physical health, and emotional wellbeing.
Step 5: Consult a Bard PowerPort Litigation Attorney
Contact a firm with active MDL 3081 experience for a free case evaluation. Most firms provide same-day or next-day initial assessments and will tell you clearly whether your case meets the current filing criteria.
Step 6: Act Before Your Statute of Limitations Expires
Do not wait for news of global settlements. Your filing deadline exists independently of MDL progress. A missed deadline permanently bars your claim.
5 Frequently Asked Questions
Q1: How do I confirm my device was specifically a Bard PowerPort? Your implant card is the most direct confirmation. If unavailable, your surgical records will name the device. Bard PowerPort devices are also identifiable on chest X-ray by a triangular CT-marker symbol embedded in the port reservoir — identifiable by a radiologist reviewing your films. If you have had any chest CT during your treatment, those images may confirm the device type.
Q2: My catheter fractured but the fragment was successfully retrieved. Can I still file a claim? Yes. The need for any retrieval procedure — regardless of its ultimate success — represents significant compensable harm. The emergency nature of catheter embolism, the retrieval procedure itself (typically performed under sedation or general anaesthesia with fluoroscopic guidance), the hospitalisation, the risk of procedural complications, the interruption of your cancer treatment, and the physical and emotional trauma all constitute damages supporting a claim.
Q3: I'm a cancer patient. Does my underlying condition complicate my claim? It is a factor that defendants will raise, but it does not disqualify your claim. Your attorneys and expert witnesses will specifically address the distinction between your cancer's prognosis and the additional harm caused by the device failure. Port failures are particularly serious in cancer patients because they interrupt treatment, compromise the only reliable venous access in some patients, and create life-threatening infections in immunocompromised individuals. These aggravating factors support stronger — not weaker — damages arguments.
Q4: My complication happened 4 years ago. Am I definitely too late? Not necessarily. The discovery rule in many states starts the limitations clock from when you knew or should reasonably have known that your complication was caused by a device defect — not simply from the date of the complication itself. If you only recently became aware that your fracture was potentially attributable to a device design issue (for example, after learning about this litigation), your limitations window may still be open. Consult an attorney immediately — this is time-sensitive.
Q5: Becton Dickinson is one of the world's largest medical device companies. Is it realistic to expect them to settle? Yes. BD has resolved device litigation previously — including the Bard IVC Filter MDL, which produced both jury verdicts and settlements. Large medical device companies settle MDL proceedings for multiple reasons: to avoid the unpredictability of jury verdicts, to limit ongoing litigation costs, to manage reputational exposure, and because bellwether trial results provide a pricing framework for global resolution. The size of the defendant is not a barrier to pursuing or recovering on a legitimate claim.
Conclusion
A venous access port is implanted to help deliver life-saving treatment. When that device fractures and sends pieces of itself toward a patient's heart — in some cases into the heart itself — the harm is not just physical. For cancer patients already enduring one of the most challenging experiences of their lives, a device failure can mean delayed treatment, additional surgery, prolonged hospitalisation, and the terror of a medical emergency on top of everything else they are facing.
Thousands of Bard PowerPort patients have lived this experience. If you are one of them, your legal rights are real, meaningful, and worth understanding. Consultations are free. Representation is contingency-based. And your filing window is open now — but not indefinitely.
Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. Settlement ranges are estimates based on comparable litigation. Consult a licensed attorney in your jurisdiction for advice specific to your situation. Statistics reflect available information as of early 2026.
Comments
Post a Comment